Vid3G, Inc. VIDG
We’re bringing VIDG up as an item of interest this morning as a stock that is coming off of its 52-week lows, and our subscribers are well aware, we’ve seen plays like these produce exponential gains on the rebound many times in the past.
Yesterday’s session saw a rapid swing up from that annual low (.01), and VIDG managed to break through its 50DMA at .015, as well as maintain that level into the close. Another session of higher highs and higher lows would go a long way toward confirming this uptrend. We’d like to see that previous area of resistance hold as support moving ahead, and based on a number of indicators on the chart, the chance for a bounce to .02 or better is certainly present; VIDG has produced spikes of that magnitude several times this year.
We illustrate this and other points on the chart in the following video, so take a look:
Petroleo Brasiliero S.A. (Petrobras) PBR – Options
On Friday, we mentioned our interest in the PBR $16 Calls for this week, and included a reminder in yesterday morning’s report as well. We’ve become quite adept at playing the PBR options chain over the last several months, and these alerts simply confirm that.
The action on the $16 Weekly Calls indeed proved to be significant as the trading week commenced, with yesterday’s session seeing an intraday move from .20-.38, good for gains of up to 90% A great way to kick things off for these contracts which are now in the money, and we’ll be sticking with the $16’s as the week presses on.
Should PBR approach the 16.35-level, we would then have to consider moving up our strike price.
IsoRay, Inc. ISR
We also want to throw ISR into the mix this morning, as the stock is gapping up off of a relative bottom on some exciting news this morning, so we wanted to enter this into the log as an interesting play that we’re going to want to keep an eye on.
RICHLAND, WA, Aug 05, 2014 (Marketwired via COMTEX) — IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the publication of the first major peer reviewed study showing superior results using IsoRay’s Cesium-131 seeds in the treatment of metastatic brain cancer. >>>FULL PR
Extended Watchlist:
ODP, ESI, GRPN, MNI, KORS